Literature DB >> 33159857

An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping.

Kenta Kawasaki1, Kohta Toshimitsu1, Mami Matano2, Masashi Fujita3, Masayuki Fujii4, Kazuhiro Togasaki1, Toshiki Ebisudani5, Mariko Shimokawa2, Ai Takano2, Sirirat Takahashi2, Yuki Ohta2, Kosaku Nanki1, Ryo Igarashi1, Kazuhiro Ishimaru4, Hiroki Ishida6, Yasutaka Sukawa1, Shinya Sugimoto1, Yoshimasa Saito7, Kazuhiro Maejima3, Shota Sasagawa3, Hwajin Lee8, Hong-Gee Kim8, Kyungsik Ha8, Junko Hamamoto9, Koichi Fukunaga9, Aya Maekawa10, Minoru Tanabe10, Soichiro Ishihara11, Yasuo Hamamoto12, Hiroyuki Yasuda9, Shigeki Sekine13, Atsushi Kudo10, Yuko Kitagawa14, Takanori Kanai12, Hidewaki Nakagawa3, Toshiro Sato15.   

Abstract

Gastroenteropancreatic (GEP) neuroendocrine neoplasm (NEN) that consists of neuroendocrine tumor and neuroendocrine carcinoma (NEC) is a lethal but under-investigated disease owing to its rarity. To fill the scarcity of clinically relevant models of GEP-NEN, we here established 25 lines of NEN organoids and performed their comprehensive molecular characterization. GEP-NEN organoids recapitulated pathohistological and functional phenotypes of the original tumors. Whole-genome sequencing revealed frequent genetic alterations in TP53 and RB1 in GEP-NECs, and characteristic chromosome-wide loss of heterozygosity in GEP-NENs. Transcriptome analysis identified molecular subtypes that are distinguished by the expression of distinct transcription factors. GEP-NEN organoids gained independence from the stem cell niche irrespective of genetic mutations. Compound knockout of TP53 and RB1, together with overexpression of key transcription factors, conferred on the normal colonic epithelium phenotypes that are compatible with GEP-NEN biology. Altogether, our study not only provides genetic understanding of GEP-NEN, but also connects its genetics and biological phenotypes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  3D culture; CRISPR-Cas9; NKX2-5; epigenome; fusion gene; gastrinoma; lineage reprogramming; multi-omics; stem cell niche; transcription factors

Mesh:

Substances:

Year:  2020        PMID: 33159857     DOI: 10.1016/j.cell.2020.10.023

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  31 in total

1.  Creeping fat in Crohn's disease explained.

Authors:  Iain Dickson
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12       Impact factor: 46.802

2.  Organoid biobanks as a new tool for pre-clinical validation of candidate drug efficacy and safety.

Authors:  Gerardo Botti; Maurizio Di Bonito; Monica Cantile
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2021-02-15

Review 3.  WNT as a Driver and Dependency in Cancer.

Authors:  Marie J Parsons; Tuomas Tammela; Lukas E Dow
Journal:  Cancer Discov       Date:  2021-09-13       Impact factor: 39.397

Review 4.  Promises and Challenges of Organoid-Guided Precision Medicine.

Authors:  Shree Bose; Hans Clevers; Xiling Shen
Journal:  Med (N Y)       Date:  2021-09-10

5.  Patient-derived tumor organoids for personalized medicine in a patient with rare hepatocellular carcinoma with neuroendocrine differentiation: a case report.

Authors:  Marie-Anne Meier; Sandro Nuciforo; Mairene Coto-Llerena; John Gallon; Matthias S Matter; Caner Ercan; Jürg Vosbeck; Luigi M Terracciano; Savas D Soysal; Daniel Boll; Otto Kollmar; Raphaël Delaloye; Salvatore Piscuoglio; Markus H Heim
Journal:  Commun Med (Lond)       Date:  2022-07-01

6.  Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.

Authors:  Fabrice Viol; Bence Sipos; Martina Fahl; Till S Clauditz; Tania Amin; Malte Kriegs; Maike Nieser; Jakob R Izbicki; Samuel Huber; Ansgar W Lohse; Jörg Schrader
Journal:  Cell Oncol (Dordr)       Date:  2022-10-21       Impact factor: 7.051

7.  The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.

Authors:  Job van Riet; Harmen J G van de Werken; Edwin Cuppen; Ferry A L M Eskens; Margot Tesselaar; Linde M van Veenendaal; Heinz-Josef Klümpen; Marcus W Dercksen; Gerlof D Valk; Martijn P Lolkema; Stefan Sleijfer; Bianca Mostert
Journal:  Nat Commun       Date:  2021-07-29       Impact factor: 14.919

8.  Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity.

Authors:  Xiaohan Shi; Yunguang Li; Qiuyue Yuan; Shijie Tang; Shiwei Guo; Yehan Zhang; Juan He; Xiaoyu Zhang; Ming Han; Zhuang Liu; Yiqin Zhu; Suizhi Gao; Huan Wang; Xiongfei Xu; Kailian Zheng; Wei Jing; Luonan Chen; Yong Wang; Gang Jin; Dong Gao
Journal:  Nat Commun       Date:  2022-04-21       Impact factor: 17.694

Review 9.  Organoids and Colorectal Cancer.

Authors:  Antonio Barbáchano; Asunción Fernández-Barral; Pilar Bustamante-Madrid; Isabel Prieto; Nuria Rodríguez-Salas; María Jesús Larriba; Alberto Muñoz
Journal:  Cancers (Basel)       Date:  2021-05-28       Impact factor: 6.639

Review 10.  Reconstructing the tumor architecture into organoids.

Authors:  Zhimin Luo; Xingwu Zhou; Kalpana Mandal; Na He; Wally Wennerberg; Moyuan Qu; Xing Jiang; Wujin Sun; Ali Khademhosseini
Journal:  Adv Drug Deliv Rev       Date:  2021-06-19       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.